[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2900694T3 - Dwuswoiste przeciwciała igg jako aktywatory komórek t - Google Patents

Dwuswoiste przeciwciała igg jako aktywatory komórek t

Info

Publication number
PL2900694T3
PL2900694T3 PL13777349T PL13777349T PL2900694T3 PL 2900694 T3 PL2900694 T3 PL 2900694T3 PL 13777349 T PL13777349 T PL 13777349T PL 13777349 T PL13777349 T PL 13777349T PL 2900694 T3 PL2900694 T3 PL 2900694T3
Authority
PL
Poland
Prior art keywords
igg antibodies
bispecific igg
cell engagers
engagers
cell
Prior art date
Application number
PL13777349T
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Pieter Fokko VAN LOO
Ton Logtenberg
Original Assignee
Merus N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus N.V. filed Critical Merus N.V.
Publication of PL2900694T3 publication Critical patent/PL2900694T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL13777349T 2012-09-27 2013-09-27 Dwuswoiste przeciwciała igg jako aktywatory komórek t PL2900694T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261706543P 2012-09-27 2012-09-27
US201361834915P 2013-06-14 2013-06-14
PCT/NL2013/050693 WO2014051433A1 (en) 2012-09-27 2013-09-27 BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
EP13777349.5A EP2900694B1 (en) 2012-09-27 2013-09-27 Bispecific igg antibodies as t cell engagers

Publications (1)

Publication Number Publication Date
PL2900694T3 true PL2900694T3 (pl) 2018-12-31

Family

ID=49382559

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13777349T PL2900694T3 (pl) 2012-09-27 2013-09-27 Dwuswoiste przeciwciała igg jako aktywatory komórek t

Country Status (27)

Country Link
US (2) US10358492B2 (pl)
EP (2) EP2900694B1 (pl)
JP (2) JP6471095B2 (pl)
KR (1) KR102390177B1 (pl)
CN (2) CN105051066B (pl)
AU (2) AU2013324527B9 (pl)
BR (1) BR112015006824A2 (pl)
CA (1) CA2889681C (pl)
CY (1) CY1120976T1 (pl)
DK (1) DK2900694T3 (pl)
EA (1) EA201590640A1 (pl)
ES (1) ES2692951T3 (pl)
HK (1) HK1211966A1 (pl)
HR (1) HRP20181717T1 (pl)
HU (1) HUE042040T2 (pl)
IL (1) IL237945B (pl)
LT (1) LT2900694T (pl)
MX (1) MX2015003885A (pl)
NZ (1) NZ630563A (pl)
PL (1) PL2900694T3 (pl)
PT (1) PT2900694T (pl)
RS (1) RS57910B1 (pl)
SG (2) SG11201502451QA (pl)
SI (1) SI2900694T1 (pl)
TR (1) TR201815768T4 (pl)
WO (1) WO2014051433A1 (pl)
ZA (1) ZA201502835B (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP1523496B1 (en) 2002-07-18 2011-06-29 Merus B.V. Recombinant production of mixtures of antibodies
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
SG190726A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
NZ799532A (en) 2012-04-20 2023-07-28 Merus Nv Methods and means for the production of ig-like molecules
HUE042040T2 (hu) * 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10351626B2 (en) * 2013-03-14 2019-07-16 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
JP2016534051A (ja) * 2013-07-04 2016-11-04 フラウンホーファ−ゲゼルシャフト ツァー フォルデルング デア アンゲバンデン フォルシュンク エー． ファオ．Ｆｒａｕｎｈｏｆｅｒ−Ｇｅｓｅｌｌｓｃｈａｆｔ Ｚｕｒ Ｆｏｒｄｅｒｕｎｇ Ｄｅｒ Ａｎｇｅｗａｎｄｔｅｎ Ｆｏｒｓｃｈｕｎｇ Ｅ． Ｖ． 急性骨髄性白血病細胞を標的化および処置するための新規融合タンパク質
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN107109420A (zh) 2014-07-21 2017-08-29 诺华股份有限公司 使用cll－1嵌合抗原受体的癌症治疗
EP3693391B1 (en) 2014-09-12 2024-08-21 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
LT3221359T (lt) 2014-11-17 2020-07-27 Regeneron Pharmaceuticals, Inc. Naviko gydymo būdai, naudojant cd3xcd20 bispecifinį antikūną
PT3221357T (pt) * 2014-11-20 2020-07-28 Hoffmann La Roche Cadeias leves comuns e métodos de utilização
ES2926673T3 (es) 2014-11-20 2022-10-27 Hoffmann La Roche Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1
KR20180006367A (ko) * 2015-02-13 2018-01-17 소렌토 쎄라퓨틱스, 인코포레이티드 Ctla4에 결합하는 항체 치료제
KR20240007967A (ko) * 2015-03-04 2024-01-17 주식회사유한양행 Cd47에 결합하는 항체 치료제
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
EA201890028A1 (ru) 2015-07-10 2018-08-31 Мерус Н.В. Антитело, связывающее cd3 человека
HUE057683T2 (hu) * 2015-09-23 2022-05-28 Regeneron Pharma Optimalizált anti-CD3 bispecifikus antitestek és alkalmazásaik
CN108602888B (zh) 2015-10-23 2022-10-04 美勒斯公司 抑制癌症生长的结合分子
CN108347906A (zh) * 2015-10-29 2018-07-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
EP3405492B1 (en) 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
WO2017210443A1 (en) * 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
US20190307799A1 (en) 2016-09-23 2019-10-10 The Regents Of The University Of Michigan Engineered lymphocytes
MX2019009468A (es) * 2017-02-08 2020-01-20 Dragonfly Therapeutics Inc Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
KR20190120782A (ko) * 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
RU2019129511A (ru) * 2017-02-20 2021-03-22 Драгонфлай Терапьютикс, Инк. Белки, связывающие gd2, nkg2d и cd16
CA3058343A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
CN111278455A (zh) * 2017-05-23 2020-06-12 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
AU2018273250A1 (en) * 2017-05-23 2019-12-12 Dragonfly Therapeutics, Inc. A protein binding NKG2D, CD16 and a tumor-associated antigen
WO2019009726A1 (en) 2017-07-06 2019-01-10 Merus N.V. BINDING MOLECULES FOR MODULATING THE BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
IL313753A (en) 2017-07-06 2024-08-01 Merus Nv Bispecific antibodies against PD1 and against TIM3
TW201920275A (zh) * 2017-07-06 2019-06-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
AU2018312816B2 (en) 2017-08-09 2021-05-27 Merus N.V. Antibodies that bind EGFR and cMET
BR112020005078A2 (pt) * 2017-09-14 2020-10-13 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16, e molécula 1 semelhante a lecitina de tipo c (cll-1)
JP7230819B2 (ja) 2017-10-06 2023-03-01 小野薬品工業株式会社 二重特異性抗体
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
EP3717008A1 (en) 2017-12-01 2020-10-07 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
CN111936514A (zh) * 2018-03-30 2020-11-13 美勒斯公司 多价抗体
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
JP7440102B2 (ja) * 2018-06-22 2024-02-28 キュージーン インコーポレイテッド 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
US11590223B2 (en) 2018-08-31 2023-02-28 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
WO2020081841A1 (en) * 2018-10-19 2020-04-23 Regents Of The University Of Minnesota Nk engager molecules and methods of use thereof
US12129305B2 (en) 2018-10-25 2024-10-29 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L for treatment and prevention of cancer
WO2020130829A1 (en) 2018-12-20 2020-06-25 Merus N.V. Clec12axcd3 bispecific antibodies and methods for the treatment of disease
WO2020141974A1 (en) 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
TW202102544A (zh) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
MX2021013417A (es) * 2019-05-04 2021-12-10 Inhibrx Inc Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
TW202118790A (zh) 2019-07-30 2021-05-16 日商小野藥品工業股份有限公司 雙特異性抗體
JPWO2021025140A1 (pl) 2019-08-08 2021-02-11
BR112022007219A2 (pt) * 2019-10-17 2022-07-05 Univ Minnesota Sequências de fragmento de anticorpo clec12a e métodos
IL294181A (en) 2019-12-24 2022-08-01 Merus Nv tgf-beta-rii binding proteins
CN115697402A (zh) * 2020-05-06 2023-02-03 蜻蜓疗法股份有限公司 靶向clec12a的抗体及其用途
MX2023001556A (es) 2020-08-05 2023-03-08 Dragonfly Therapeutics Inc Anticuerpos que se dirigen a egfr y uso de los mismos.
US20230111279A1 (en) * 2021-04-26 2023-04-13 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
EP4373856A1 (en) * 2021-07-20 2024-05-29 ABL Bio Inc. Anti-cll-1 antibodies and uses thereof
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
GB202214132D0 (en) * 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ATE243747T1 (de) 1991-07-15 2003-07-15 Wellcome Found Herstellung von antikörpern
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (en) * 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
DK1533380T3 (da) 1999-04-15 2010-02-01 Crucell Holland Bv Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus
DE60219221T2 (de) 2001-07-04 2008-01-03 Chromagenics B.V. DNS-Sequenzen mit anti-repressor Aktivität
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
EP1523496B1 (en) * 2002-07-18 2011-06-29 Merus B.V. Recombinant production of mixtures of antibodies
EP1578947A4 (en) * 2002-12-02 2006-12-06 Abgenix Inc ANTIBODIES AGAINST A2 PHOSPHOLIPASE AND USES
ES2273202T3 (es) 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005000894A2 (en) 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
UA94211C2 (ru) * 2004-06-03 2011-04-26 Новиммюн С.А. Выделенное полностью человеческое моноклональное cd3 антитело
BRPI0511782B8 (pt) 2004-06-03 2021-05-25 Novimmune Sa anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
SE527196C2 (sv) 2004-07-08 2006-01-17 Chemel Ab SIRE genomflödesdetektor
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US20060171929A1 (en) 2005-01-31 2006-08-03 The University Of Washington Regulation of dendritic cell functions by the DCAL-2 receptor
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
GB2429517B (en) 2005-07-15 2010-10-06 Viridian Concepts Ltd Solar collector devices
CN101309703A (zh) 2005-09-12 2008-11-19 诺维莫尼公司 抗cd3抗体组合物
US20070198410A1 (en) 2005-10-18 2007-08-23 Labgold Marc R Credit fraud prevention systems and methods
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
WO2009051974A1 (en) 2007-10-17 2009-04-23 Nuvelo, Inc. Antibodes to cll-1
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
WO2009098596A2 (en) 2008-02-05 2009-08-13 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
RU2559524C2 (ru) 2008-06-27 2015-08-10 Мерюс Б.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
WO2010084197A1 (en) 2009-01-26 2010-07-29 Genmab A/S Methods for producing mixtures of antibodies
PE20120539A1 (es) 2009-03-20 2012-05-12 Genentech Inc Anticuerpos anti-her biespecifico
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8586713B2 (en) 2009-06-26 2013-11-19 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
RS59001B1 (sr) * 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
AU2011290480B2 (en) 2010-08-16 2015-07-30 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2012235758B2 (en) 2011-03-25 2015-05-07 Ichnos Sciences SA Hetero-dimeric immunoglobulins
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
NZ799532A (en) 2012-04-20 2023-07-28 Merus Nv Methods and means for the production of ig-like molecules
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
EA201890028A1 (ru) 2015-07-10 2018-08-31 Мерус Н.В. Антитело, связывающее cd3 человека

Also Published As

Publication number Publication date
CN110066338A (zh) 2019-07-30
EP3470431A1 (en) 2019-04-17
IL237945B (en) 2022-04-01
IL237945A0 (en) 2015-05-31
SG11201502451QA (en) 2015-05-28
US12060418B2 (en) 2024-08-13
RS57910B1 (sr) 2019-01-31
US20140120096A1 (en) 2014-05-01
BR112015006824A2 (pt) 2017-07-04
WO2014051433A1 (en) 2014-04-03
AU2018204173B2 (en) 2020-05-07
ES2692951T3 (es) 2018-12-05
CN110066338B (zh) 2024-04-09
KR20150076178A (ko) 2015-07-06
HUE042040T2 (hu) 2019-06-28
EA201590640A1 (ru) 2015-11-30
CN105051066A (zh) 2015-11-11
PT2900694T (pt) 2018-11-13
AU2013324527A1 (en) 2015-05-14
AU2018204173A1 (en) 2018-06-28
CY1120976T1 (el) 2020-05-29
EP2900694A1 (en) 2015-08-05
US10358492B2 (en) 2019-07-23
JP2019068803A (ja) 2019-05-09
KR102390177B1 (ko) 2022-04-26
EP2900694B1 (en) 2018-09-12
AU2013324527B9 (en) 2018-07-26
LT2900694T (lt) 2018-11-12
MX2015003885A (es) 2015-07-06
CA2889681C (en) 2023-04-11
TR201815768T4 (tr) 2018-11-21
SG10201705787VA (en) 2017-08-30
JP6471095B2 (ja) 2019-02-20
DK2900694T3 (en) 2018-11-19
CN105051066B (zh) 2019-08-06
NZ630563A (en) 2017-04-28
AU2013324527B2 (en) 2018-05-24
ZA201502835B (en) 2016-01-27
HRP20181717T1 (hr) 2018-12-28
CA2889681A1 (en) 2014-04-03
JP2015532278A (ja) 2015-11-09
HK1211966A1 (en) 2016-06-03
US20190352393A1 (en) 2019-11-21
SI2900694T1 (sl) 2018-12-31

Similar Documents

Publication Publication Date Title
HRP20181717T1 (hr) Bispecifična igg protutijela kao aktivatori t stanice
HUS2400016I1 (hu) FCRN elleni antitestek
HK1217958A1 (zh) 四價雙特異性抗體
HK1210620A1 (en) Multi-specific monoclonal antibodies
EP2922874A4 (en) BISPECIFIC ANTIBODIES
HK1202563A1 (en) Sequence symmetric modified igg4 bispecific antibodies igg4
HK1209137A1 (en) Humanized tau antibody tau
PT2825559T (pt) Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
HK1202565A1 (en) Sequence symmetric modified igg4 bispecific antibodies igg4
HK1204571A1 (en) Protease-regulated antibodies
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
ZA201407272B (en) Anti-baff-anti-il-17 bispecific antibodies
HK1210186A1 (en) Anti-h7cr antibodies h7cr
HK1202454A1 (en) Anti-p-selectin antibody formulation -p-